Are HMO physicians more price sensitive in prescribing brand-name drugs?

被引:1
|
作者
Rice, Jennifer L. [1 ]
机构
[1] Eastern Michigan Univ, Dept Econ, Ypsilanti, MI 48197 USA
关键词
Health services; Medical care; Medical prescriptions; Doctors; Prices; Drugs;
D O I
10.1108/17506120910989642
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose - The purpose of this paper is to estimate whether health maintenance organizations (HMO) physicians are more price sensitive than non-HMO physicians in their prescribing behavior of brand-name substitutes. Design/methodology/approach - The study uses physician level data and a set of 13 drugs for the years 1997-2000 to estimate the price sensitivity of HMO and non-HMO physicians. A two-part model is used to measure the price elasticity of brand-name prescribing for HMO physicians. The first part uses a logit model to examine the physician's choice to prescribe the same drug to all patients with the same medical condition, or whether physicians alternate prescriptions among brand-name substitutes. The second part employs OLS to estimate the influence of managed care, i.e. HMOs, on physician price sensitivity. Findings - The results suggest that HMO physicians are less likely than non-HMO physicians to prescribe a common drug to all patients with a specific medical condition, but rather HMO physicians exhibit more diversified prescribing behavior. Correspondingly, HMO physicians are more price sensitive in prescribing brand-name substitutes, than non-HMO physicians, exhibiting price elasticities of prescribing ranging from -1.707 to -1.823. The analysis suggests that HMOs have a modest influence on encouraging physicians to be more price sensitive in their prescribing of brand-name substitutes. HMO physicians are more price sensitive in their prescribing behavior than non-HMO physicians. Originality/value - This paper provides insight into the effectiveness of HMOs in altering physician prescribing behavior and price sensitivity of pharmaceutical prices. The results provide suggestions on how HMOs can improve the cost-effectiveness of physician prescribing behavior.
引用
收藏
页码:184 / 209
页数:26
相关论文
共 50 条
  • [1] Industry Payments to Physicians and Prescribing of Brand-name Drugs
    Steinbrook, Robert
    JAMA INTERNAL MEDICINE, 2016, 176 (08) : 1123 - 1123
  • [2] The effect of generic competition on the price of brand-name drugs
    Lexchin, J
    HEALTH POLICY, 2004, 68 (01) : 47 - 54
  • [3] Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts
    Yeh, James S.
    Franklin, Jessica M.
    Avorn, Jerry
    Landon, Joan
    Kesselheim, Aaron S.
    JAMA INTERNAL MEDICINE, 2016, 176 (06) : 763 - 768
  • [4] Physicians are more likely than non-physicians to use brand-name drugs to treat their chronic conditions
    Carrera, Mariana
    Skipper, Niels
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2017, 71 (09) : 874 - 881
  • [5] SUBSTITUTION FOR BRAND-NAME DRUGS
    CAMINETSKY, S
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1963, 88 (18) : 950 - &
  • [6] The adverse effects of brand-name drug prescribing
    Flegel, Ken
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2012, 184 (05) : 616 - 616
  • [7] Brand-Name Versus Generic Drugs
    Manning, Richard
    Smith, Richard
    HEALTH AFFAIRS, 2011, 30 (10) : 2027 - 2027
  • [8] Generic script share and the price of brand-name drugs: the role of consumer choice
    Rizzo, John A.
    Zeckhauser, Richard
    INTERNATIONAL JOURNAL OF HEALTH CARE FINANCE & ECONOMICS, 2009, 9 (03): : 291 - 316
  • [9] Generic script share and the price of brand-name drugs: the role of consumer choice
    John A. Rizzo
    Richard Zeckhauser
    International Journal of Health Care Finance and Economics, 2009, 9 : 291 - 316
  • [10] The Value of Specifying Brand-name Antiepileptic Drugs
    Ng, Yu-tze
    ARCHIVES OF NEUROLOGY, 2009, 66 (11) : 1415 - 1416